Months post gene therapy 23 For 5 patients, increased BM CFC MMC resistance ranging from 51% to 94% was observed at 18 to 24 months post– RP-L102 administration 25 Disease etiology 26 24 Months post gene therapy RP-L201: LAD-I INVESTOR DECK INVESTOR DECK INVESTOR DECK 41st Annual J.P. Morgan Healthcare Conference Company Presentation Gaurav Shah, MD Chief Executive Officer January 9, 2023 DISCLAIMER Various statements in this presentation concerning Rocket's future expectations, plans and prospects, includi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (609) 659-8001 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: | Title of each class | Trading Symbol(s) | Name of each exchange on ...

REN@VAC@R | --- | --- | --- | |----------------------------------|-------|-------| | | | | | RENOVACOR CORPORATE PRESENTATION | | | | NYSE: RCOR | | | | September 2022 | | | | | | | | | | | Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this communication that do not relate to matters of historical fact should be considered forward-looking statements, including statements ...

INVESTOR DECK INVESTOR DECK INVESTOR DECK SEEKING GENE THERAPY CURES DISCLAIMER Various statements in this release concerning Rocket's future expectations, plans and prospects, including without limitation, Rocket's expectations regarding its guidance for 2022 in light of COVID-19, the safety, effectiveness and timing of product candidates that Rocket may develop, to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), and Danon Disease, and the safety, effec ...

REN@VAC@R | --- | --- | --- | |----------------------------------|-------|-------| | | | | | RENOVACOR CORPORATE PRESENTATION | | | | NYSE: RCOR | | | | September 2022 | | | | | | | | | | | Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this communication that do not relate to matters of historical fact should be considered forward-looking statements, including statements ...

| --- | --- | |---------------|--------------------------------------------------------| | | | | INVESTOR DECK | INVESTOR DECK INVESTOR DECK SEEKING GENE THERAPY CURES | | | | DISCLAIMER regarding its guidance for 2022 in light of COVID-19, the safety, effectiveness and timing of product candidates that Rocket may develop, to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), and Danon Disease, and the safety, effectiveness and timing of related pre-clinica ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36829 Rocket Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or ...

Rocket Program Updates Following ASGCT 2022 Danon Disease, Pyruvate Kinase Deficiency, Fanconi Anemia, and Leukocyte Adhesion Deficiency-I 1 Gaurav Shah, MD Chief Executive Officer May 20, 2022 S E E K I N G G E N E T H E R A P Y C U R E S NASDAQ: RCKT 2 Cautionary Statement Regarding Forward-Looking Statements Various statements in this release concerning Rocket's future expectations, plans and prospects, including without limitation, Rocket's expectations regarding its guidance for 2022 in light of COVID- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36829 Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted purs ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36829 Rocket Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 04-3475813 (State or Other Jurisdic ...